Bedrijfsoverzicht
Alnylam Pharmaceuticals, Inc. is a biotechnology enterprise dedicated to discovering, developing, manufacturing, and commercializing therapeutics that utilize ribonucleic acid interference technology across the United States, Europe, and international markets. The company operates within the healthcare sector, specifically targeting the biotechnology industry, where innovation in genetic medicine drives significant clinical and commercial development. With a market capitalization of $42.72 billion, annual revenue of $3.71 billion, and an employee base of 2500, Alnylam represents a substantial entity within the specialized pharmaceutical landscape. These valuation and revenue figures indicate that the company has achieved a significant scale, positioning it as a major player capable of sustaining high research and development expenditures while commercializing complex therapies for conditions such as hereditary transthyretin-mediated amyloidosis.
Financiële gezondheid
Alnylam reported a trailing twelve-month revenue of $3.71 billion, generating net income of $313.75 million and an EBITDA of $557.24 million during the same period. The substantial gap between the total revenue of $3.71 billion and the net income of $313.75 million reveals a cost structure where operating expenses, research costs, and overhead consume approximately 91.6% of gross revenue before reaching the bottom line. The company generated free cash flow of $128.79 million, which signifies a positive operational efficiency that provides the financial flexibility to fund ongoing clinical trials without relying solely on external capital markets. Profitability metrics show a gross margin of 81.6%, an operating margin of 12.0%, and a profit margin of 8.4%, indicating that while the company retains a high portion of sales revenue after the cost of goods sold, significant operational expenditures impact the final bottom line. Regarding liquidity and leverage, the company holds cash assets of $2.91 billion against total debt of $2.97 billion, resulting in a debt-to-equity ratio of 376.19 which suggests a highly leveraged balance sheet structure relative to equity. The current ratio stands at 2.76, indicating a robust short-term liquidity position where current assets are nearly three times the value of current liabilities. Return on equity is reported at an impressive 73.3% while return on assets is 6.8%, revealing that management is highly effective at generating returns on shareholders' equity, although the return on assets is moderated by the company's significant asset base and debt obligations.
Waarderingsbeoordeling
Alnylam's trailing P/E ratio is 138.84, while the forward P/E ratio is significantly lower at 22.68, implying that the market expects a dramatic improvement in earnings trajectory to align current high valuations with future performance. The price-to-book ratio stands at 54.03, indicating that the stock trades at a substantial market premium over its net asset book value, reflecting investor confidence in the company's intangible assets and pipeline potential. Alternative valuation metrics include a price-to-sales ratio of 11.50 and an EV/EBITDA of 76.77, suggesting that the market values the company primarily on its revenue generation and future cash flow potential rather than current earnings. The stock's 52-week trading range spans from a low of $225.84 to a high of $495.55, providing context for the current price volatility and historical price action within the biotechnology sector. The beta value is 0.38, which indicates that the stock price exhibits significantly lower volatility relative to the broader market, moving less than half as much as the market index during periods of fluctuation.
Growth & Income
The company demonstrates robust revenue growth of 84.9% year-over-year, while earnings growth is listed as N/A, indicating that revenue expansion is currently outpacing any reported earnings growth or that earnings data is not yet standardized for year-over-year comparison. For non-dividend payers like Alnylam, the company reinvests its earnings into research, development, and commercialization efforts rather than distributing income to shareholders, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This strategy allows the firm to allocate capital toward expanding its therapeutic portfolio and advancing its pipeline of RNA interference-based medicines. The overall growth and income profile is characterized by rapid top-line expansion funded by strong cash generation and a lack of dividend distribution, focusing entirely on long-term market capture and technological advancement.